Abstract

IMiDs compounds are a class of analogues of thalidomide, with greater immunomodulatory activity and a superior safety profile compared to the parent compound. They show substantial increase in potency and an interesting tolerability profile, primarily due to a decreased incidence of the most severe side effect of thalidomide, i.e. Chemotherapy- Induced Peripheral Neurotoxicity (CIPN). These novel aspects of the IMiDs compounds will be discussed.

Keywords: IMiDs, thalidomide, CC-5013, lenalidomide, CC-4047, pomalidomide, safety, side effects, CIPN